The study will examine the effects of intranasally administered long-acting insulin detemir on cognition in people with Alzheimer's disease or amnestic mild cognitive impairment (aMCI).
|Min Age||Max Age||Gender||Healthy Volunteers|
There is growing evidence that insulin contributes to multiple brain functions and that insulin dysregulation can contribute to Alzheimer's disease pathogenesis. Therapies aimed at restoring normal insulin signaling in the central nervous system may have beneficial effects on brain function. Intranasal administration of insulin increases insulin signaling in the brain without raising peripheral levels and causing hypoglycemia (abnormally low blood sugar).
Insulin detemir is an insulin analogue that may have better action in the brain than other insulin formulations because of its albumin-binding properties. Participants will receive insulin detemir, regular insulin, or placebo over a 4-month period. The investigators will test the hypothesis that insulin and insulin detemir will both improve memory and daily functioning in people with Alzheimer's or MCI compared with placebo, but that insulin detemir will have the greatest effect.
|Map Marker||City||State||Zip Code|
Geolocation is 47.2528139, -122.4443415
University of Washington
Suzanne Craft, PhD
VA Puget Sound HCS/University of Washington School of Medicine
Julie Moorer, RN